Physician profile
Hamid Habibi
NPI 1194018366
$1,822.60
in general payments reported to CMS, 2019-2025
15 companies · $395 in 2025
The $395 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $420 · 2020: $122 · 2021: $62.25 · 2022: $244 · 2023: $295 · 2024: $283 · 2025: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $973.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $739.93 | 2019-2025 | |
| Pfizer INC. | $202.40 | 2019-2024 | |
| Allergan, INC. | $167.25 | 2019-2020 | |
| Celgene Corporation | $151.44 | 2023-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $110.34 | 2019-2023 | Entyvio |
| Boston Scientific Corporation | $99.38 | 2019 | |
| Janssen Biotech, INC. | $73.08 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.63 | 2019-2025 | Xifaxan |
| Janssen Scientific Affairs, LLC | $62.57 | 2025 | |
| Genzyme Corporation | $56.42 | 2023 | |
| Upsher-Smith Laboratories LLC | $22.53 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $19.85 | 2023 | Dupixent |
| Novartis Pharmaceuticals Corporation | $18.89 | 2019 | |
| Intercept Pharmaceuticals, INC. | $16.58 | 2022 | |
| Merck Sharp & Dohme LLC | $12.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hamid Habibi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.